Carlyle To Acquire Baxter's Kidney Care Segment, To Be Named Vantive, For $3.8B
Portfolio Pulse from Benzinga Newsdesk
Carlyle Group is set to acquire Baxter International's Kidney Care segment for $3.8 billion. The segment will be renamed Vantive post-acquisition.
August 13, 2024 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baxter International is selling its Kidney Care segment to Carlyle Group for $3.8 billion. This divestiture could streamline Baxter's operations and potentially improve its financial health.
The sale of the Kidney Care segment for $3.8 billion will provide Baxter with significant capital, which can be used to pay down debt or reinvest in core areas. This could lead to a positive short-term impact on Baxter's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Carlyle Group is acquiring Baxter's Kidney Care segment for $3.8 billion, which will be renamed Vantive. This acquisition could enhance Carlyle's portfolio in the healthcare sector.
The acquisition of Baxter's Kidney Care segment for $3.8 billion will expand Carlyle's presence in the healthcare sector, potentially leading to positive investor sentiment and a short-term boost in Carlyle's stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100